Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy
Immunotherapy agents in metastatic non-small cell lung cancer (NSCLC) can result in improved quality of life and survival when compared with platinum-based chemotherapy. Novel response patterns such as pseudoprogression and hyperprogression, however, have been described and pose a challenge to treating physicians. Predictors of hyperprogressive disease (HPD) have not yet been identified. Evaluation and management by a multidisciplinary team involving medical and radiation oncologists, thoracic radiologists, and proceduralists is necessary to identify this subset of patients in a timely manner. Repeat biopsy distinguishes HPD from pseudoprogression and may eventually elucidate predictive biomarkers. We describe the epidemiology of these two phenomena, their diagnostic criteria, and their relevance for interventional pulmonologists.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of thoracic disease - 10(2018), 2 vom: 28. Feb., Seite 1124-1128 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kurman, Jonathan S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hyperprogressive disease (HPD) |
|---|
| Anmerkungen: |
Date Revised 30.09.2020 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/jtd.2018.01.79 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM28256666X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM28256666X | ||
| 003 | DE-627 | ||
| 005 | 20231226194932.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/jtd.2018.01.79 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0941.xml |
| 035 | |a (DE-627)NLM28256666X | ||
| 035 | |a (NLM)29607190 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kurman, Jonathan S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Immunotherapy agents in metastatic non-small cell lung cancer (NSCLC) can result in improved quality of life and survival when compared with platinum-based chemotherapy. Novel response patterns such as pseudoprogression and hyperprogression, however, have been described and pose a challenge to treating physicians. Predictors of hyperprogressive disease (HPD) have not yet been identified. Evaluation and management by a multidisciplinary team involving medical and radiation oncologists, thoracic radiologists, and proceduralists is necessary to identify this subset of patients in a timely manner. Repeat biopsy distinguishes HPD from pseudoprogression and may eventually elucidate predictive biomarkers. We describe the epidemiology of these two phenomena, their diagnostic criteria, and their relevance for interventional pulmonologists | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Hyperprogressive disease (HPD) | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a non-small cell lung cancer (NSCLC) | |
| 650 | 4 | |a pseudoprogression | |
| 700 | 1 | |a Murgu, Septimiu D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic disease |d 2012 |g 10(2018), 2 vom: 28. Feb., Seite 1124-1128 |w (DE-627)NLM219116938 |x 2072-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2018 |g number:2 |g day:28 |g month:02 |g pages:1124-1128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/jtd.2018.01.79 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2018 |e 2 |b 28 |c 02 |h 1124-1128 | ||